Linked Life Data

19709980

Source:http://linkedlifedata.com/resource/pubmed/id/19709980

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19709980rdf:typepubmed:Citationlld:pubmed
pubmed-article:19709980lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:19709980lifeskim:mentionsumls-concept:C0701159lld:lifeskim
pubmed-article:19709980lifeskim:mentionsumls-concept:C0012634lld:lifeskim
pubmed-article:19709980lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:19709980lifeskim:mentionsumls-concept:C0011570lld:lifeskim
pubmed-article:19709980lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:19709980lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:19709980lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:19709980pubmed:issue6lld:pubmed
pubmed-article:19709980pubmed:dateCreated2009-11-25lld:pubmed
pubmed-article:19709980pubmed:abstractTextOur objective was to study the clinical and management differences between primary and interferon (IFN)-induced depressive disorders in malignant melanoma patients visited by the consultation-liaison team during a two year period. This was a prospective study of 31 patients with malignant melanoma treated with IFN-alpha in a general teaching hospital. Clinical, psychiatric variables and DSM-IV-TR diagnosis were analyzed. The Clinical Global Impression Severity (CGI-S) and Improvement (CGI-I) of illness scales were administered at the time of consultation and at the end of hospitalization. The main diagnoses were depressive adjustment disorders in 14 patients (45.16%) followed by interferon-induced depressive disorders in 6 (19.36%). In patients with adjustment disorders, melanoma stage was significantly more advanced than in those with interferon-induced depressive disorder (p = 0.019). The latter scored higher in the CGI-S scale (p = 0.044) and in the CGI-I scale (p = 0.029). The interferon-induced depressive disorders, except one who required a reduction of IFN-alpha-2b dose, were successfully treated with antidepressant drugs. Clinical management and antidepressant treatment allowed the continuation of interferon therapy in malignant melanoma patients. Interferon-induced depression occurred in a few patients, which in turn were the most severe. Adjustment depressive disorder was the most common psychiatric diagnosis.lld:pubmed
pubmed-article:19709980pubmed:languageenglld:pubmed
pubmed-article:19709980pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19709980pubmed:citationSubsetIMlld:pubmed
pubmed-article:19709980pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19709980pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19709980pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19709980pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19709980pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19709980pubmed:statusMEDLINElld:pubmed
pubmed-article:19709980pubmed:issn1167-1122lld:pubmed
pubmed-article:19709980pubmed:authorpubmed-author:Gómez-GilEsth...lld:pubmed
pubmed-article:19709980pubmed:authorpubmed-author:PuigSusanaSlld:pubmed
pubmed-article:19709980pubmed:authorpubmed-author:Martín-Santos...lld:pubmed
pubmed-article:19709980pubmed:authorpubmed-author:De PabloJoanJlld:pubmed
pubmed-article:19709980pubmed:authorpubmed-author:BaezaInmacula...lld:pubmed
pubmed-article:19709980pubmed:authorpubmed-author:NavinésRicard...lld:pubmed
pubmed-article:19709980pubmed:issnTypePrintlld:pubmed
pubmed-article:19709980pubmed:volume19lld:pubmed
pubmed-article:19709980pubmed:ownerNLMlld:pubmed
pubmed-article:19709980pubmed:authorsCompleteYlld:pubmed
pubmed-article:19709980pubmed:pagination611-5lld:pubmed
pubmed-article:19709980pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:meshHeadingpubmed-meshheading:19709980...lld:pubmed
pubmed-article:19709980pubmed:articleTitleDepression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders.lld:pubmed
pubmed-article:19709980pubmed:affiliationUnitat de Recerca Farmacològica, Institut Municipal d'Investigació Mèdica, Doctor Aiguader 88, E-08003, Barcelona, Spain. rnavines@hotmail.comlld:pubmed
pubmed-article:19709980pubmed:publicationTypeJournal Articlelld:pubmed